Protalix BioTherapeutics (Protalix BioTherapeutics) Interest Expense : $-3.19 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Protalix BioTherapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Protalix BioTherapeutics's interest expense for the three months ended in Dec. 2023 was $ -0.77 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.19 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Protalix BioTherapeutics's Operating Income for the three months ended in Dec. 2023 was $ -5.62 Mil. Protalix BioTherapeutics's Interest Expense for the three months ended in Dec. 2023 was $ -0.77 Mil. Protalix BioTherapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Protalix BioTherapeutics Interest Expense Historical Data

The historical data trend for Protalix BioTherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Interest Expense Chart

Protalix BioTherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-7.97

-9.67

-7.52

-2.53

-3.18

Protalix BioTherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.65	-0.65	-1.31	-0.46	-0.77

Protalix BioTherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.19 Mil.

Protalix BioTherapeutics (AMEX:PLX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Protalix BioTherapeutics's Interest Expense for the three months ended in Dec. 2023 was $-0.77 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-5.62 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $4.62 Mil.

Protalix BioTherapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Protalix BioTherapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (AMEX:PLX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

PBDA:Germany

Address

2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601

Website

https://www.protalix.com

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

Executives

Dror Bashan	director, officer: President and CEO	2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100
Eliot Forster	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Aharon Schwartz	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Zvi Shmuel Ben	director	2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Eyal Rubin	officer: Sr. VP and CFO	C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601
Yaron Naos	officer: Sr. VP, Operations	2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100
Yael Hayon	officer: Vice President, R&D	2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401
Zeev Bronfeld	director	6 URI STREET, TEL AVIV L3 64954
Amos Bar-shalev	director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
David Granot	director	6225 NEIL ROAD, RENO NV 89511
Pol F Boudes	director	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Moshe Manor	officer: President & CEO	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100